Merck V114 Vaccine Meets Primary Endpoint in Phase 2 Study

Date : 08/05/2019 @ 15h56
Source : Dow Jones News
Valeur : Merck and Co Inc (MRK)
Cours : 84.99  0.3 (0.35%) @ 20h39
Merck Cours Graphique

Merck V114 Vaccine Meets Primary Endpoint in Phase 2 Study

Merck (NYSE:MRK)
Graphique Historique de l'Action

6 Mois : De Avr 2019 à Oct 2019

Plus de graphiques de la Bourse Merck

By Colin Kellaher


Merck & Co. (MRK) on Wednesday said a phase 2 study of V114, its investigational 15-valent pneumococcal conjugate vaccine in infants six to 12 weeks of age, met its primary endpoint.

The Kenilworth, N.J., drug maker said V114 showed noninferiority to PCV13, the currently available 13-valent vaccine, for the 13 serotypes contained in both vaccines.

V114 also induced an immune response in infants for two additional disease-causing serotypes not contained in PCV13, the company added.

Merck said the data support continued progression of its phase 3 studies of V114. The company's V114 development program currently comprises 11 phase 3 trials.

Merck in January received breakthrough-therapy designation from the U.S. Food and Drug Administration for V114 for the prevention of invasive pneumococcal disease in pediatric patients six weeks to 18 years of age.

The FDA's breakthrough-therapy designation aims to expedite the development and review of a drug for serious conditions when preliminary clinical evidence shows the drug may show substantial improvement over available therapies.


Write to Colin Kellaher at


(END) Dow Jones Newswires

May 08, 2019 09:41 ET (13:41 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Dernières Valeurs Consultées
Société Gé..
CAC 40
Euro vs Do..
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.

Inscrivez-vous maintenant pour créer votre liste d'actions personnalisée, en streaming.

Les cours EURONEXT (CAC 40, etc. ) et FOREX (les devises) sont en direct si connecté.
NYSE, AMEX, et ASX sont en différé d'environ 20 minutes. Les autres cours sont en différé d'environ 15 minutes.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Conditions Générales

P: V:fr D:20191015 18:54:05